Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Abnormal Proliferation02:23

Abnormal Proliferation

4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Mismatch Repair01:20

Mismatch Repair

4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.

Experimental hematology·2026
Same author

Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.

Blood advances·2026
Same author

Evaluation of Long-Read Genome Sequencing for Genomic Profiling of Myeloid Cancers.

The Journal of molecular diagnostics : JMD·2025
Same author

A clinical guide to TP53 mutations in myeloid neoplasms.

Blood·2025
Same author

Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy.

Nature genetics·2025
Same author

How chemotherapy shapes hematopoietic stem cells.

Nature genetics·2025
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
查看所有相关文章

相关实验视频

Updated: Jun 5, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.5K

所有TP53突变都是一样的吗?

Terrence N Wong1, Daniel C Link2

  • 1Division of Hematology-Oncology, University of Michigan, Ann Arbor, MI.

Hematology. American Society of Hematology. Education Program
|December 7, 2024
PubMed
概括
此摘要是机器生成的。

TP53突变在急性髓性白血病 (AML) 和骨髓显样性综合征 (MDS) 中很常见,影响患者的预后. 多击TP53突变,特别是热点突变,与糟糕的结果有关,需要进行特定的遗传测试以进行管理.

更多相关视频

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

10.8K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

相关实验视频

Last Updated: Jun 5, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.5K
Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

10.8K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 分子生物学分子生物学

背景情况:

  • TP53突变发生在10-15%的急性髓性白血病 (AML) 和骨髓质综合征 (MDS) 病例中.
  • 这些突变与先前的细胞毒性治疗,复杂的细胞遗传学和不良预后有关.
  • 突变TP53等位基因的状态至关重要,需要进行特定的遗传测试.

研究的目的:

  • 审查AML/MDS中TP53突变的证据.
  • 讨论TP53突变状态对患者结局的影响.
  • 探索TP53突变AML/MDS的潜在临床管理策略.

主要方法:

  • 对AML/MDS中TP53突变的现有数据的文献综述.
  • 分析TP53突变等位基因状态及其与临床特征的相关性.
  • 检查突变类型,包括DNA结合域中的热点突变.

主要成果:

  • 与单基性疾病相比,多击TP53突变AML/MDS显示染色体异常增加和整体存活率降低.
  • 大多数TP53突变都是DNA结合域内的误解突变.
  • 热点突变 (R175,Y220,G245,R248,R273,R282) 在AML/MDS中约占TP53误解突变的35%.

结论:

  • TP53热点突变可能表现出主导负或功能获取的特性.
  • 了解TP53突变状态对于预测AML/MDS患者的结果至关重要.
  • 这些知识可以为受影响患者的临床管理和治疗决策提供信息.